Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001628280-22-007102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-03-23 | 2022-03-21 | STLN | SARIN RAVI YANG | Dir | A - Grant | $0.00 | +23.2K | 23.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2022-03-21 | A | A | 15,994 | $0.00 | 15,994 | D | — | — | (F1) Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. |
| 2 | Common | Common stock | 2022-03-21 | A | A | 7,197 | $0.00 | 23,191 | D | — | — |